T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

A bispecific antibody comprising a first antigen-binding site that binds an EBV-LMP2/HLA peptide complex and a second antigen-binding site, wherein the first antigen-binding site comprises

• (a) heavy chain CDR1 of SEQ ID NO:31, heavy chain CDR2 of SEQ ID NO:33 and heavy chain CDR3 of SEQ ID NO:35;
• and light chain CDR1 of SEQ ID NO:73, light chain CDR2 of SEQ ID NO:75 and light chain CDR3 of SEQ ID NO:77;
• (b) heavy chain CDR1 of SEQ ID NO:37, heavy chain CDR2 of SEQ ID NO:39 and heavy chain CDR3 of SEQ ID NO:41;
• and light chain CDR1 of SEQ ID NO:79, light chain CDR2 of SEQ ID NO:81 and light chain CDR3 of SEQ ID NO:83;
• (c) heavy chain CDR1 of SEQ ID NO:43, heavy chain CDR2 of SEQ ID NO:45 and heavy chain CDR3 of SEQ ID NO:47;
• and light chain CDR1 of SEQ ID NO:85, light chain CDR2 of SEQ ID NO:87 and light chain CDR3 of SEQ ID NO:89;
• (d) heavy chain CDR1 of SEQ ID NO:49, heavy chain CDR2 of SEQ ID NO:51 and heavy chain CDR3 of SEQ ID NO:53;
• and light chain CDR1 of SEQ ID NO:91, light chain CDR2 of SEQ ID NO:93 and light chain CDR3 of SEQ ID NO:95;
• (e) heavy chain CDR1 of SEQ ID NO:55, heavy chain CDR2 of SEQ ID NO:57 and heavy chain CDR3 of SEQ ID NO:59;
• and light chain CDR1 of SEQ ID NO:97, light chain CDR2 of SEQ ID NO:99 and light chain CDR3 of SEQ ID NO:101;
• (f) heavy chain CDR1 of SEQ ID NO:61, heavy chain CDR2 of SEQ ID NO:63 and heavy chain CDR3 of SEQ ID NO:65;
• and light chain CDR1 of SEQ ID NO:103, light chain CDR2 of SEQ ID NO:105 and light chain CDR3 of SEQ ID NO:107;
• or
• (g) heavy chain CDR1 of SEQ ID NO:67, heavy chain CDR2 of SEQ ID NO:69 and heavy chain CDR3 of SEQ ID NO:71, and light chain CDR1 of SEQ ID NO:109, light chain CDR2 of SEQ ID NO:111 and light chain CDR3 of SEQ ID NO:113.